The study is to be performed in public health facilities in Central and West Africa where
Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat
episodes. The study is to assess the safety of Pyramax, particularly in patients with
underlying liver function abnormalities, in patients who have co-morbid conditions, such as
HIV, and also in very small children (<1 year of age).